Curis, Inc. (CRIS) Receives Average Rating of “Hold” from Brokerages

Shares of Curis, Inc. (NASDAQ:CRIS) have earned an average rating of “Hold” from the seven analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.67.

A number of research firms recently commented on CRIS. ValuEngine raised shares of Curis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub raised shares of Curis from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 17th. Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Cowen and Company reissued a “buy” rating on shares of Curis in a research report on Monday, May 15th.

ILLEGAL ACTIVITY WARNING: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://transcriptdaily.com/2017/09/06/curis-inc-cris-receives-average-rating-of-hold-from-brokerages.html.

A number of institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its position in Curis by 1.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 1,880 shares during the period. Rhumbline Advisers boosted its position in Curis by 1.9% in the 2nd quarter. Rhumbline Advisers now owns 127,529 shares of the biotechnology company’s stock valued at $241,000 after buying an additional 2,340 shares during the period. American International Group Inc. boosted its position in Curis by 7.1% in the 1st quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 4,560 shares during the period. Weiss Multi Strategy Advisers LLC boosted its position in Curis by 4.8% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 130,000 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 6,000 shares during the period. Finally, Dynamic Technology Lab Private Ltd boosted its position in Curis by 22.3% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 7,638 shares during the period. 50.94% of the stock is owned by institutional investors.

Curis (CRIS) opened at 2.15 on Wednesday. The company has a 50-day moving average of $1.83 and a 200-day moving average of $2.15. The company’s market capitalization is $309.34 million. Curis has a 1-year low of $1.47 and a 1-year high of $3.72.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.01. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The firm had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $2.08 million. During the same period in the prior year, the firm posted ($0.09) earnings per share. Curis’s revenue for the quarter was up 23.5% on a year-over-year basis. Equities analysts expect that Curis will post ($0.40) EPS for the current fiscal year.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply